Johnson & Johnson is expected to seek Food and Drug Administration authorization for its COVID-19 booster shot this week. The J&J single-shot vaccine is only 71% effective against hospitalization, according to a recent Centers for Disease Control and Prevention study. (The New York Times)

GlaxoSmithKline will provide 10,000 doses of its COVID-19 monoclonal antibody treatment to Canada, the company announced. “New therapies like sotrovimab are important for treating the disease in its early stages,” said Ranya El Masri, head of government affairs and market access for GSK Canada. (Reuters)

Targeted electrical stimulation of the brain was shown to be effective in reducing depression symptoms, according to a new study. The study focused on NeuroPace, a device which has been given an investigational exemption by the FDA but is not yet approved for general use in treating depression. (STAT)

As part of an effort to bolster its bispecifics pipeline, Janssen has signed a $100 million licensing deal with Xencor. The deal will grant J&J access to Xencor’s CD20/CD3 bispecific antibody plamotamab, which is being tested for treatment of B cell malignancies. (Endpoints News)

Centrist Democrats are fighting to limit Medicare expansion of dental, vision and hearing care to only the poorest Americans. Some industry groups, including the American Dental Association, argue that limiting coverage expansion would help save funds. (Politico)